BR112015004452A2 - sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares - Google Patents

sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares

Info

Publication number
BR112015004452A2
BR112015004452A2 BR112015004452A BR112015004452A BR112015004452A2 BR 112015004452 A2 BR112015004452 A2 BR 112015004452A2 BR 112015004452 A BR112015004452 A BR 112015004452A BR 112015004452 A BR112015004452 A BR 112015004452A BR 112015004452 A2 BR112015004452 A2 BR 112015004452A2
Authority
BR
Brazil
Prior art keywords
compositions
methods
sirna
prevention
treatment
Prior art date
Application number
BR112015004452A
Other languages
English (en)
Inventor
Isabel Jimenez Anton Ana
Ruz Palomar Veronica
Gonzalez Fajardo Victoria
Original Assignee
Sylentis Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis Sau filed Critical Sylentis Sau
Publication of BR112015004452A2 publication Critical patent/BR112015004452A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Abstract

resumo da patente de invenção para: "sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares". a presente invenção se refere a métodos, composições e dosagens que diminuem a pressão intraocular do olho compreendendo uma molécula de rna fita dupla de 19 nucleotídeos.
BR112015004452A 2012-09-05 2012-09-05 sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares BR112015004452A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2012/052177 WO2014037686A1 (en) 2012-09-05 2012-09-05 Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions

Publications (1)

Publication Number Publication Date
BR112015004452A2 true BR112015004452A2 (pt) 2017-08-08

Family

ID=46889366

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015004452A BR112015004452A2 (pt) 2012-09-05 2012-09-05 sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares

Country Status (19)

Country Link
US (1) US10011832B2 (pt)
EP (1) EP2893018B1 (pt)
JP (1) JP2015533792A (pt)
KR (1) KR102120060B1 (pt)
CN (1) CN104781402A (pt)
AU (1) AU2012389270B2 (pt)
BR (1) BR112015004452A2 (pt)
CA (1) CA2883007A1 (pt)
CL (1) CL2015000538A1 (pt)
EC (1) ECSP15011105A (pt)
ES (1) ES2750125T3 (pt)
HK (1) HK1211983A1 (pt)
IL (1) IL237403B (pt)
IN (1) IN2015DN02699A (pt)
MX (1) MX368084B (pt)
RU (1) RU2653766C2 (pt)
SG (1) SG11201501385UA (pt)
WO (1) WO2014037686A1 (pt)
ZA (1) ZA201502181B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015004452A2 (pt) 2012-09-05 2017-08-08 Sylentis Sau sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares
WO2015132303A1 (en) * 2014-03-04 2015-09-11 Sylentis Sau Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343794A (en) 1980-05-06 1982-08-10 Mt. Sinai Method of reducing intraocular pressure with salts of vanadic acid
US4652586A (en) 1980-11-07 1987-03-24 The General Hospital Corporation Selective beta-2 adrenergic antagonists for the treatment of glaucoma
SU986484A1 (ru) * 1981-07-20 1983-01-07 Каунасский Политехнический Институт Им.Антанаса Снечкуса Дозатор жидкости
US4617299A (en) 1983-12-19 1986-10-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US5242943A (en) 1984-03-28 1993-09-07 William J. Louis 3-aminopropoxyphenyl derivatives, their preparation and pharmaceutical compositions containing them
US4812448A (en) 1984-10-22 1989-03-14 Knepper Paul A Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension
US4757089A (en) 1985-06-14 1988-07-12 Massachusetts Eye And Ear Infirmary Increasing aqueous humor outflow
US5075323A (en) 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
US5260059A (en) 1989-04-14 1993-11-09 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University Treatment of open-angle glaucoma by modulation matrix metalloproteinases and their inhibitor
RU2039539C1 (ru) * 1990-09-27 1995-07-20 Менчел Йехошуа Насадка для установки на флаконе с лекарственной жидкостью и устройство для распределения глазной жидкости
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5464866A (en) 1992-08-17 1995-11-07 Alcon Laboratories, Inc. Substituted hydrindanes for the treatment of angiogenesis-dependent diseases
US5545626A (en) 1994-01-19 1996-08-13 The Trustees Of Columbia University In The City Of New York Method of treating glaucoma with oligonucleotides
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US20020055536A1 (en) 1996-09-26 2002-05-09 Dewitte Robert S. System and method for structure-based drug design that includes accurate prediction of binding free energy
US6489307B1 (en) 1998-09-14 2002-12-03 University Of Florida Antisense compositions targeted to β1-adrenoceptor-specific mRNA and methods of use
EP1147204A1 (en) 1999-01-28 2001-10-24 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
US6365576B1 (en) 1999-06-24 2002-04-02 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for inhibiting herpes infection
WO2002044321A2 (en) 2000-12-01 2002-06-06 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Rna interference mediating small rna molecules
US20020165158A1 (en) 2001-03-27 2002-11-07 King George L. Methods of modulating angiogenesis
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20070049543A1 (en) 2001-05-18 2007-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 11 beta-hydroxysteroid dehydrogenase-1 (11 beta-HSD-1) gene expression using short interfering nucleic acid siNA
EP1587574A4 (en) 2001-12-21 2009-03-18 Rhode Island Hospital 11b-HSD SELECTIVE INHIBITORS AND METHODS OF USE
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
GB2406568B (en) 2002-02-20 2005-09-28 Sirna Therapeutics Inc RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
AU2003222820A1 (en) 2002-04-18 2003-10-27 Acuity Pharmaceuticals, Inc. Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
RU2332213C2 (ru) 2002-04-30 2008-08-27 Алькон, Инк. Агенты, которые регулируют, ингибируют или модулируют активность и/или экспрессию факторов роста соединительной ткани (фрст), в качестве уникальных средств для снижения внутриглазного давления и лечения глаукоматозных ретинопатий/оптических невропатий
US20040115641A1 (en) 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of ROCK 1 expression
DE20209155U1 (de) 2002-06-13 2003-10-23 Eugen Beck Gmbh & Co Dr Brille, insbesondere fassungslose Bohr-Brille
IL165910A0 (en) * 2002-07-03 2006-01-15 Pericor Science Inc Compositions of hyaluronic acid and methods of use
US20040146858A1 (en) 2002-07-24 2004-07-29 Immusol, Inc. Novel siRNA gene libraries and methods for their production and use
EP1554386A2 (en) 2002-07-24 2005-07-20 Immusol Incorporated Single promoter system for making sirna expression cassettes and expression libraries using a polymerase primer hairpin linker
DK3222724T3 (en) 2002-08-05 2018-12-03 Silence Therapeutics Gmbh ADDITIONALLY UNKNOWN FORMS OF INTERFERRING RNA MOLECULES
US20040029275A1 (en) 2002-08-10 2004-02-12 David Brown Methods and compositions for reducing target gene expression using cocktails of siRNAs or constructs expressing siRNAs
CA2881743A1 (en) 2002-09-25 2004-04-08 University Of Massachusetts In vivo gene silencing by chemically modified and stable sirna
KR20050083855A (ko) 2002-11-01 2005-08-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US7250496B2 (en) 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20060257851A1 (en) 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US20040167090A1 (en) 2003-02-21 2004-08-26 Monahan Sean D. Covalent modification of RNA for in vitro and in vivo delivery
GB0307206D0 (en) 2003-03-28 2003-04-30 Axordia Ltd Hyperproliferation
US20040198640A1 (en) 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
WO2004099372A2 (en) 2003-05-01 2004-11-18 University Of Florida Anti-scarring ribozymes and methods
US20040224405A1 (en) 2003-05-06 2004-11-11 Dharmacon Inc. siRNA induced systemic gene silencing in mammalian systems
EP1636342A4 (en) 2003-06-20 2008-10-08 Isis Pharmaceuticals Inc OLIGOMERIC COMPOUNDS FOR GENE MODULATION
MXPA06003949A (es) 2003-10-07 2006-06-27 Renovis Inc Compuestos amida como ligandos del canal de ion y su uso.
WO2005045037A2 (en) 2003-10-23 2005-05-19 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF 5-ALPHA REDUCTASE AND ANDROGEN RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20050208658A1 (en) 2003-11-21 2005-09-22 The University Of Maryland RNA interference mediated inhibition of 11beta hydroxysteriod dehydrogenase-1 (11beta HSD-1) gene expression
WO2005076998A2 (en) 2004-02-05 2005-08-25 Intradigm Corporation Rnai therapeutics for treatment of eye neovascularization diseases
GB0403600D0 (en) 2004-02-18 2004-03-24 Trinity College Dublin Methods and reagents for treating disease
EP2365077B1 (en) 2004-03-12 2013-05-08 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
KR101147147B1 (ko) 2004-04-01 2012-05-25 머크 샤프 앤드 돔 코포레이션 Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
WO2005117938A2 (en) 2004-04-13 2005-12-15 Regents Of The University Of Minnesota Methods of treating ocular conditions
IL179285A (en) 2004-05-14 2011-04-28 Rosetta Genomics Ltd Micrornas and uses thereof
JP2008504280A (ja) 2004-06-24 2008-02-14 インサイト・コーポレイション ２−メチルプロパンアミドおよびその医薬としての使用
US7582744B2 (en) 2004-08-10 2009-09-01 Alnylam Pharmaceuticals, Inc. Chemically modified oligonucleotides
SI1781787T1 (sl) 2004-08-23 2017-08-31 Sylentis S.A.U. Zdravljenje očesnih nepravilnosti, kakakterističnih za povišan očesni tlak s sirna
TW200639252A (en) 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular hypertension targets
CA2598234A1 (en) 2005-03-11 2006-09-21 Alcon, Inc. Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
JP2010501188A (ja) * 2006-08-24 2010-01-21 アルコン リサーチ， リミテッド ＩＯＰに関連した病態の処置のためのグレムリンのＲＮＡｉ媒介阻害
US20100292301A1 (en) 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
BR112015004452A2 (pt) 2012-09-05 2017-08-08 Sylentis Sau sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares

Also Published As

Publication number Publication date
RU2015112131A (ru) 2016-10-27
ZA201502181B (en) 2016-01-27
ES2750125T3 (es) 2020-03-25
AU2012389270B2 (en) 2018-11-08
SG11201501385UA (en) 2015-03-30
CA2883007A1 (en) 2014-03-13
MX368084B (es) 2019-09-19
RU2653766C2 (ru) 2018-05-14
EP2893018A1 (en) 2015-07-15
MX2015002800A (es) 2015-07-17
AU2012389270A1 (en) 2015-02-26
IL237403A0 (en) 2015-04-30
CN104781402A (zh) 2015-07-15
IN2015DN02699A (pt) 2015-09-04
WO2014037686A1 (en) 2014-03-13
CL2015000538A1 (es) 2015-07-31
EP2893018B1 (en) 2019-07-24
ECSP15011105A (es) 2015-12-31
US10011832B2 (en) 2018-07-03
KR102120060B1 (ko) 2020-06-09
JP2015533792A (ja) 2015-11-26
US20150259677A1 (en) 2015-09-17
HK1211983A1 (en) 2016-06-03
KR20150048880A (ko) 2015-05-07
IL237403B (en) 2019-11-28

Similar Documents

Publication Publication Date Title
CL2019000107A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.(divisional solicitud 201702014)
AU2024201770A1 (en) Complement component iRNA compositions and methods of use thereof
BR112015009624A2 (pt) inibidores de tirosina cinase de bruton
BR112015007985A2 (pt) compostos do carboidrato galactose denteada para o tratamento de nefropatia diabética e distúrbios associados
WO2014022739A3 (en) Modified rnai agents
PH12015502310B1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2018012038A (es) Agentes de iarn modificados.
BR112017016663A2 (pt) oligômero, conjugado, composição, kit, e, métodos para inibir ou reduzir a expressão de proteína tau em uma célula e para tratar ou prevenir um distúrbio neurológico
MX2019009283A (es) Composiciones de arni de proteina convertasa subtilisina kexina 9 (pcsk9) y metodos de uso de las mismas.
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
BR112014021498A2 (pt) composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado
BR112015018438A2 (pt) anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
BR112013031032A2 (pt) inibidores de sglt-2 para o tratamento de distúrbios metabólicos em pacientes tratados com agentes neurolépticos
BR112014000380A2 (pt) composição farmacêutica, métodos para tratamento e usos dos mesmos
BR112015023797A2 (pt) proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17
BR112014006587A8 (pt) Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
BR112015022825A2 (pt) métodos de diagnóstico, seleção e tratamento de doenças e condições causadas por ou associadas a metanógenos
BR112015000616A2 (pt) tratamento da esclerose múltipla com combinação de laquinimode e fampridina
IN2014DN08385A (pt)
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
BR112015004469A2 (pt) sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares
BR112015002979B8 (pt) Forma cristalina, e, composição farmacêutica
BR112014024033A8 (pt) Formulação vesicular, método para o tratamento da rosácea e uso de um ou mais fosfo, sulfolipídios e surfactantes
BR112014000889A2 (pt) tratamento para hipoxia
BR112015004452A2 (pt) sirna e seu uso em métodos e composições para o tratamento e/ou prevenção de condições oculares

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements